文献速递乳腺癌

基于人群的乳腺癌胚系基因关联研究及荟萃分析:为更广泛的主流检测提供依据

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
PubMed 文献 · Ann Oncol · 2024-07-08

该研究对BRIDGES、CARRIERS和UK Biobank三项基于人群的病例对照研究进行加权荟萃分析,共纳入101397例乳腺癌女性和312944例无乳腺癌女性,量化37个推定乳腺癌易感基因在未选择的「人群型」乳腺癌病例中的致病变异频率及其与乳腺癌及亚型的关联。结果显示BRCA1、BRCA2和PALB2的OR分别为8.73、5.68和4.30,PV频率分别为1/101、1/68和1/187;CHEK2和ATM与雌激素受体阳性疾病关联更强;RAD51C、RAD51D和BARD1的关联强度和频率较低,但限制于三阴性乳腺癌时频率和关联更高;TP53、STK11、CDH1、PTEN和NF1等「综合征型」基因的PV频率很低,关联指标也较温和。

要点

  • BRCA1、BRCA2和PALB2在「人群型」乳腺癌中PV频率分别为1/101、1/68和1/187,OR分别为8.73、5.68和4.30。
  • CHEK2和ATM与雌激素受体阳性乳腺癌关联更强,OR分别为2.40和2.16。
  • RAD51C、RAD51D和BARD1总体频率低,但限制于三阴性乳腺癌时频率和关联更高。

核心结论

  • 这些反映「人群型」乳腺癌的指标将有助于在胚系检测范围不断扩大至越来越未选择的乳腺癌病例时,界定合适的基因集。

研究设计与样本

  • 对BRIDGES、CARRIERS和UK Biobank三项基于人群的病例对照研究进行加权荟萃分析。
  • 共纳入101397例乳腺癌女性和312944例无乳腺癌女性,量化37个推定乳腺癌易感基因。

主要发现

  • BRCA1的OR为8.73(95%CI 7.47-10.20),PV频率为1/101;BRCA2的OR为5.68(95%CI 5.13-6.30),PV频率为1/68;PALB2的OR为4.30(95%CI 3.68-5.03),PV频率为1/187。
  • CHEK2的OR为2.40(95%CI 2.21-2.62),PV频率为1/73;ATM的OR为2.16(95%CI 1.93-2.41),PV频率为1/132;亚组分析显示两者与雌激素受体阳性疾病的关联更强。
  • RAD51C的OR为1.53(95%CI 1.29-2.04),PV频率为1/913;RAD51D的OR为1.76(95%CI 1.29-2.41),PV频率为1/1079;BARD1的OR为2.34(95%CI 1.85-2.97),PV频率为1/672;限制于三阴性乳腺癌时频率和关联更高。
  • 「综合征型」基因TP53的PV频率为1/1844,STK11为1/11525,CDH1为1/2668,PTEN为1/3755,NF1为1/1470;关联指标从TP53的OR 3.62(95%CI 1.98-6.61)到STK11的OR 1.60(95%CI 0.48-5.30)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Germline genetic testing, previously restricted to familial and young-onset breast cancer, is now offered increasingly broadly to patients with 'population-type' breast cancer in mainstream oncology clinics, with wide variation in the genes included. PATIENTS AND METHODS: Weighted meta-analysis was carried out for three population-based case-control studies (BRIDGES, CARRIERS and UK Biobank) comprising in total 101 397 women with breast cancer and 312 944 women without breast cancer, to quantify 37 putative breast cancer susceptibility genes (BCSGs) for the frequency of pathogenic variants (PVs) in unselected, 'population-type' breast cancer cases and their association with breast cancer and its subtypes. RESULTS: Meta-analysed odds ratios (ORs) and frequencies of PVs in 'population-type' breast cancer cases were generated for BRCA1 (OR 8.73, 95% confidence interval (CI) 7.47-10.20; 1 in 101), BRCA2 (OR 5.68, 95% CI 5.13-6.30; 1 in 68) and PALB2 (OR 4.30, 95% CI 3.68-5.03; 1 in 187). For both CHEK2 (OR 2.40, 95% CI 2.21-2.62; 1 in 73) and ATM (OR 2.16, 95% CI 1.93-2.41; 1 in 132) subgroup analysis showed a stronger association with oestrogen receptor-positive disease. The magnitude of association and frequency of PVs were low for RAD51C (OR 1.53, 95% CI 1.29-2.04; 1 in 913), RAD51D (OR 1.76, 95% CI 1.29-2.41; 1 in 1079) and BARD1 (OR 2.34, 95% CI 1.85-2.97; 1 in 672); frequencies and associations were higher when the analysis was restricted to triple-negative breast cancers. The PV frequency in 'population-type' breast cancer cases was very low for 'syndromic' BCSGs TP53 (1 in 1844), STK11 (1 in 11 525), CDH1 (1 in 2668), PTEN (1 in 3755) and NF1 (1 in 1470), with metrics of association also modest ranging from OR 3.62 (95% CI 1.98-6.61) for TP53 down to OR 1.60 (95% CI 0.48-5.30) for STK11. CONCLUSIONS: These metrics reflecting 'population-type' breast cancer will be informative in defining the appropriate gene set as we continue to expand to germline testing to an increasingly unselected group of breast cancer cases.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rowlands CF, Allen S, Balmaña J, et al. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Ann Oncol. 2024. PMID: 38986768. doi:10.1016/j.annonc.2024.07.244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。